Coagulation factor VIII

• The test material is blood.
• The patient must not be on high-molecular-weight heparin treatment.
• The patient does not need to be fasting.

Samples brought from outside are not accepted for testing.

Factor VIII (FVIII, anti-hemophilic factor A, platelet factor I).
Determination of coagulation factor VIII is performed in the diagnosis of venous thromboembolism of unclear cause, in the diagnosis of FVIII deficiency, hemophilia, in cases of abnormal bleeding and in cases of abnormal aPTT results.
FVIII is formed in the liver, spleen, placenta and megakaryocytes as an inactive form. Activation occurs under the influence of thrombin and factor Xa. It participates in stabilizing cross-linked fibrin. Factor VIII in the circulation is found in complex with von Willebrand factor, which may be related to arterial thrombosis.
Decreased FVIII activity occurs in:
- conditions of increased fibrinolysis
- von Willebrand disease
- valproic acid treatment
- hemophilia A ( congenital FVIII deficiency)
- acquired hemophilia ( acquired FVIII deficiency)
The most common of the acquired inhibitors of clotting factors ( 5 cases per 1 million), acquired FVIII inhibitor occurs in the form of life-threatening hemorrhagic diathesis in women in the first weeks after pregnancy, cancer and autoimmune diseases and after surgery, in people > 60 years of age.
Increased FVIII activity occurs in:
- liver damage
- cancer
- acute and chronic infections
- inflammation
- major trauma, surgical confluence
- nephrotic syndrome
- glucocorticosteroid therapy
- acute phase of venous or arterial thrombosis

Enter a one-time code:Show
An invalid code has been entered. Please try again.